# reload+after+2024-01-21 20:43:32.094633
address1§The MediaWorks
address2§191 Wood Lane White City
city§London
zip§W12 7FP
country§United Kingdom
phone§44 20 3829 6230
website§https://www.autolus.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
fullTimeEmployees§399
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Christian Martin Itin Ph.D.', 'age': 59, 'title': 'CEO & Director', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 2737804, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Martin  Pule M.D., MBBS', 'age': 51, 'title': 'Founder, Senior VP & Chief Scientific Officer', 'yearBorn': 1972, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Christopher  Vann', 'age': 58, 'title': 'Senior VP & COO', 'yearBorn': 1965, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. David  Brochu', 'age': 67, 'title': 'Senior VP & Chief Technical Officer', 'yearBorn': 1956, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Brent  Rice', 'age': 57, 'title': 'Senior VP, Chief Commercial Officer & Site Head of US', 'yearBorn': 1966, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Edgar E. W. Braendle M.D., Ph.D.', 'age': 63, 'title': 'Senior VP & Chief Development Officer', 'yearBorn': 1960, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Robert F. Dolski', 'age': 53, 'title': 'Chief Financial Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Olivia  Manser', 'title': 'Director of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Chris  Williams', 'age': 43, 'title': 'Senior Vice President of Corporate Development', 'yearBorn': 1980, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Alexander  Swan', 'title': 'Chief Human Resources Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.786
priceToSalesTrailing12Months§197.83649
currency§USD
dateShortInterest§1702598400
forwardEps§-0.87
exchange§NMS
quoteType§EQUITY
shortName§Autolus Therapeutics plc
longName§Autolus Therapeutics plc
firstTradeDateEpochUtc§1529674200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§da5466ad-c9a9-3bae-a4e5-c7afee3582d0
gmtOffSetMilliseconds§-18000000
targetHighPrice§12.0
targetLowPrice§4.8
targetMeanPrice§9.08
targetMedianPrice§9.5
recommendationMean§1.9
recommendationKey§buy
numberOfAnalystOpinions§10
quickRatio§7.948
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
